Tetrahydrocannabinolic acid reduces nausea-induced conditioned gaping in rats and vomiting in Suncus murinus

British Journal of Pharmacology

Volumn 170, Issue 3, 2013, Pages 641-648

  Rock, E M ^a   Kopstick, R L ^a   Limebeer, C L ^a   Parker, L A ^a  

^a UNIVERSITY OF GUELPH   (Canada)

Author keywords

CB1 receptor; conditioned gaping; SR141716; THC; THCA; vomiting

Indexed keywords

LITHIUM CHLORIDE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; RIMONABANT; TETRAHYDROCANNABINOLIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR; CONDITIONED GAPING; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG MECHANISM; FEMALE; FLAVOR; INDUCED HYPOTHERMIA; LOCOMOTION; LOW DRUG DOSE; MALE; NAUSEA; NONHUMAN; PRIORITY JOURNAL; RAT; SHREW; SUNCUS MURINUS; VOMITING;

CB1 RECEPTOR; CONDITIONED GAPING; SR141716; THC; THCA; VOMITING;

ANIMALS; ANTIEMETICS; BEHAVIOR, ANIMAL; BODY TEMPERATURE REGULATION; BRAIN; CANNABINOID RECEPTOR ANTAGONISTS; DISEASE MODELS, ANIMAL; DRONABINOL; LITHIUM CHLORIDE; MALE; MOTOR ACTIVITY; NAUSEA; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, CANNABINOID, CB1; SHREWS; TIME FACTORS; VOMITING;

EID: 84884556282     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12316     Document Type: Article

References (46)

1. Ahmed SA, Ross SA, Slade D, Radwan MM, Zulfiqar F, Matsumoto RR, et al. (2008). Cannabinoid ester constituents from high-potency Cannabis sativa. J Nat Prod 71: 536-542.
2. Bolognini D, Rock EM, Cluny NL, Cascio MG, Limebeer CL, Duncan M, et al. (2013). Cannabidiolic acid prevents vomiting in Suncus murinus and nausea-induced behaviour in rats by enhancing 5-HT1A receptor activation. Br J Pharmacol 168: 1456-1470.
3. Carey MP, Burish TG, Brenner DE, (1983). Delta-9-tetrahydrocannabinol in cancer chemotherapy: research problems and issues. Ann Intern Med 99: 106-114.
4. Cluny NL, Naylor RJ, Whittle BA, Javid FA, (2008). The effects of cannabidiol and tetrahydrocannabinol on motion-induced emesis in Suncus murinus. Basic Clin Pharmacol Toxicol 103: 150-156.
5. Cohen-Yeshurun A, Trembovler V, Alexandrovich A, Ryberg E, Greasley PJ, Mechoulam R, et al. (2011). N-arachidonoyl-L-serine is neuroprotective after traumatic brain injury by reducing apoptosis. J Cereb Blood Flow Metab 31: 1768-1777.
6. Cohen-Yeshurun A, Willner D, Trembovler V, Alexandrovich A, Mechoulam R, Shohami E, et al. (2013). N-arachidonoyl-L-serine (AraS) possesses proneurogenic properties in vitro and in vivo after traumatic brain injury. J Cereb Blood Flow Metab 33: 1242-1250.
7. Cotter J, (2009). Efficacy of crude marijuana and synthetic delta-9-tetrahydrocannabinol as treatment for chemotherapy-induced nausea and vomiting: a systematic literature review. Oncol Nurs Forum 36: 345-352.
8. Crawford SM, Buckman R, (1986). Nabilone and metoclopramide in the treatment of nausea and vomiting due to cisplatinum: a double blind study. Med Oncol Tumor Pharmacother 3: 39-42.
9. Cunningham D, Bradley CJ, Forrest GJ, Hutcheon AW, Adams L, Sneddon M, et al. (1988). A randomized trial of oral nabilone and prochlorperazine compared to intravenous metoclopramide and dexamethasone in the treatment of nausea and vomiting induced by chemotherapy regimens containing cisplatin or cisplatin analogues. Eur J Cancer Clin Oncol 24: 685-689.
10. Darmani NA, (1998). Serotonin 5-HT3 receptor antagonists prevent cisplatin-induced emesis in Cryptotis parva: a new experimental model of emesis. J Neural Transm 105: 1143-1154.
11. Darmani NA, (2001a). Delta(9)-tetrahydrocannabinol and synthetic cannabinoids prevent emesis produced by the cannabinoid CB(1) receptor antagonist/inverse agonist SR 141716A. Neuropsychopharmacology 24: 198-203.
12. Darmani NA, (2001b). Delta-9-tetrahydrocannabinol differentially suppresses cisplatin-induced emesis and indices of motor function via cannabinoid CB(1) receptors in the least shrew. Pharmacol Biochem Behav 69: 239-249.
13. Darmani NA, Johnson JC, (2004). Central and peripheral mechanisms contribute to the antiemetic actions of delta-9-tetrahydrocannabinol against 5-hydroxytryptophan-induced emesis. Eur J Pharmacol 488: 201-212.
14. Darmani NA, Janoyan JJ, Crim J, Ramirez J, (2007). Receptor mechanism and antiemetic activity of structurally-diverse cannabinoids against radiation-induced emesis in the least shrew. Eur J Pharmacol 563: 187-196.
15. Frytak S, Moertel CG, O'Fallon JR, Rubin J, Creagan ET, O'Connell MJ, et al. (1979). Delta-9-tetrahydrocannabinol as an antiemetic for patients receiving cancer chemotherapy. A comparison with prochlorperazine and a placebo. Ann Intern Med 91: 825-830.
16. Gaoni Y, Mechoulam R, (1964). Isolation, structure, and partial synthesis of an active constituent of hashish. J Am Chem Soc 86: 1646-1647.
17. Grunfeld Y, Edery H, (1969). Psychopharmacological activity of the active constituents of hashish and some related cannabinoids. Psychopharmacologia 14: 200-210.
18. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577-1579.
19. Kwiatkowska M, Parker LA, Burton P, Mechoulam R, (2004). A comparative analysis of the potential of cannabinoids and ondansetron to suppress cisplatin-induced emesis in the Suncus murinus (house musk shrew). Psychopharmacology (Berl) 174: 254-259.
20. Limebeer CL, Parker LA, (1999). Delta-9-tetrahydrocannabinol interferes with the establishment and the expression of conditioned rejection reactions produced by cyclophosphamide: a rat model of nausea. Neuroreport 10: 3769-3772.
21. Limebeer CL, Parker LA, (2000). The antiemetic drug ondansetron interferes with lithium-induced conditioned rejection reactions, but not lithium-induced taste avoidance in rats. Anim Behav Process 26: 371-384.
22. Limebeer CL, Hall G, Parker LA, (2006). Exposure to a lithium-paired context elicits gaping in rats: a model of anticipatory nausea. Physiol Behav 88: 398-403.
23. Limebeer CL, Vemuri VK, Bedard H, Lang ST, Ossenkopp KP, Makriyannis A, et al. (2010). Inverse agonism of cannabinoid CB1 receptors potentiates LiCl-induced nausea in the conditioned gaping model in rats. Br J Pharmacol 161: 336-349.
24. McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
25. Martin BR, Compton DR, Thomas BF, Prescott WR, Little PJ, Razdan RK, et al. (1991). Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs. Pharmacol Biochem Behav 40: 471-478.
26. Milman G, Maor Y, Abu-Lafi S, Horowitz M, Gallily R, Batkai S, et al. (2006). N-arachidonoyl L-serine, an endocannabinoid-like brain constituent with vasodilatory properties. Proc Natl Acad Sci U S A 103: 2428-2433.
27. Orr LE, McKernan JF, (1981). Antiemetic effect of delta 9-tetrahydrocannabinol in chemotherapy-associated nausea and emesis as compared to placebo and compazine. J Clin Pharmacol 21: 76S-80S.
28. Orr LE, McKernan JF, Bloome B, (1980). Antiemetic effect of tetrahydrocannabinol. Compared with placebo and prochlorperazine in chemotherapy-associated nausea and emesis. Arch Intern Med 140: 1431-1433.
29. Parker LA, (2003). Taste avoidance and taste aversion: evidence for two different processes. Learn Behav 31: 165-172.
30. Parker LA, Kemp SW, (2001). Tetrahydrocannabinol (THC) interferes with conditioned retching in Suncus murinus: an animal model of anticipatory nausea and vomiting (ANV). Neuroreport 12: 749-751.
31. Parker LA, Mechoulam R, (2003). Cannabinoid agonists and antagonists modulate lithium-induced conditioned gaping in rats. Integr Physiol Behav Sci 38: 133-145.
32. Parker LA, Mechoulam R, Schlievert C, (2002). Cannabidiol, a non-psychoactive component of cannabis and its synthetic dimethylheptyl homolog suppress nausea in an experimental model with rats. Neuroreport 13: 567-570.
33. Parker LA, Mechoulam R, Schlievert C, Abbott L, Fudge ML, Burton P, (2003). Effects of cannabinoids on lithium-induced conditioned rejection reactions in a rat model of nausea. Psychopharmacology (Berl) 166: 156-162.
34. Parker LA, Kwiatkowska M, Burton P, Mechoulam R, (2004). Effect of cannabinoids on lithium-induced vomiting in the Suncus murinus (house musk shrew). Psychopharmacology (Berl) 171: 156-161.
35. Parker LA, Kwiatkowska M, Mechoulam R, (2006). Delta-9- tetrahydrocannabinol and cannabidiol, but not ondansetron, interfere with conditioned retching reactions elicited by a lithium-paired context in Suncus murinus: an animal model of anticipatory nausea and vomiting. Physiol Behav 87: 66-71.
36. Parker LA, Rana SA, Limebeer CL, (2008). Conditioned nausea in rats: assessment by conditioned disgust reactions, rather than conditioned taste avoidance. Can J Exp Psychol 62: 198-209.
37. Parker LA, Limebeer CL, Rock EM, Litt DL, Kwiatkowska M, Piomelli D, (2009). The FAAH inhibitor URB-597 interferes with cisplatin- and nicotine-induced vomiting in the Suncus murinus (house musk shrew). Physiol Behav 97: 121-124.
38. Rinaldi-Carmona M, Barth F, Heaulme M, Shire D, Calandra B, Congy C, et al. (1994). SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 350: 240-244.
39. Rock E, Parker L, (2013). Effect of low doses of cannabidiolic acid and ondansetron on LiCl-induced conditioned gaping (a model of nausea-induced behaviour) in rats. Br J Pharmacol 169: 685-692.
40. Rock EM, Limebeer CL, Mechoulam R, Piomelli D, Parker LA, (2008). The effect of cannabidiol and URB597 on conditioned gaping (a model of nausea) elicited by a lithium-paired context in the rat. Psychopharmacology (Berl) 196: 389-395.
41. Rock E, Bolognini D, Limebeer C, Cascio M, Anavi-Goffer S, Fletcher P, et al. (2012). Cannabidiol, a non-psychotropic component of cannabis, attenuates vomiting and nausea-like behaviour via indirect agonism of 5-HT(1A) somatodendritic autoreceptors in the dorsal raphe nucleus. Br J Pharmacol 165: 2620-2634.
42. Tramer MR, Carroll D, Campbell FA, Reynolds DJ, Moore RA, McQuay HJ, (2001). Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMJ 323: 16-21.
43. Ungerleider JT, Andrysiak TA, Fairbanks LA, Tesler AS, Parker RG, Ungerleider JT, et al. (1984). Tetrahydrocannabinol vs. prochlorperazine. The effects of two antiemetics on patients undergoing radiotherapy. Radiology 150: 598-599.
44. Van Sickle MD, Oland LD, Ho W, Hillard CJ, Mackie K, Davison JS, et al. (2001). Cannabinoids inhibit emesis through CB1 receptors in the brainstem of the ferret. Gastroenterology 121: 767-774.
45. Verhoeckx KC, Korthout HA, van Meeteren-Kreikamp AP, Ehlert KA, Wang M, van der Greef J, et al. (2006). Unheated Cannabis sativa extracts and its major compound THC-acid have potential immuno-modulating properties not mediated by CB1 and CB2 receptor coupled pathways. Int Immunopharmacol 6: 656-665.
46. Wiley JL, Martin BR, (2003). Cannabinoid pharmacological properties common to other centrally acting drugs. Eur J Pharmacol 471: 185-193.